E. Merkle

Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group

Gϋnter von Minckwitz, G. Raab, Angelika Caputo et al. · Journal of Clinical Oncology · 2005 · 420 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up

Gerhard Gebauer, Tanja Fehm, E. Merkle et al. · Journal of Clinical Oncology · 2001 · 199 citations

Medicine, Oncology, Pathology +17

Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study

Gϋnter von Minckwitz, Serban Dan Costa, G. Raab et al. · Journal of Clinical Oncology · 2001 · 144 citations

Medicine, Oncology, Pharmacotherapy +17

Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

Gϋnter von Minckwitz, Hans‐Peter Sinn, G. Raab et al. · Breast Cancer Research · 2008 · 121 citations · Full text

Medicine, Oncology, Pharmacology +13

Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer—results of the analysis of 670 patients with 11 years of follow-up

S. D. Costa, Simon de Lange, K. Klinga et al. · European Journal of Cancer · 2002 · 60 citations

Medicine, Endocrinology, Oncology +15